File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications

TitleChanges in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications
Authors
Issue Date2008
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.com
Citation
Journal Of Clinical Gastroenterology, 2008, v. 42 n. 5, p. 533-538 How to Cite?
AbstractBACKGROUND: The modified histology activity index (HAI) score has been extensively used as an additional primary or secondary end point in most phase III pivotal therapeutic clinical trials on chronic hepatitis B. Improvement in modified HAI after antiviral therapy has usually been defined as a 2-point reduction in modified HAI score. AIM: We studied whether a 2-point change in modified HAI score after antiviral therapy for chronic hepatitis B is associated with progression to liver complications (decompensated cirrhosis or hepatocellular carcinoma). METHOD: Eighty-nine patients treated with interferon-α with liver biopsy before and at 6 to 12 months after the end of therapy were followed-up for a median 119.4 months. RESULTS: At the time of analysis, 11 patients (12.4%) had liver complications. Liver complications were higher in patients with a 2-point increase in modified HAI score [8 of 19 patients (42.1%) vs. 3 of 70 patients (4.3%), P=0.0002] and in those with severe fibrosis at end of therapy [6 of 19 patients (31.6%) vs. 5 of 70 patients (7.1%), P=0.010]. On Cox regression analysis, a 2-point increase in modified HAI score was associated with increased liver complications (relative risk 5.564, P=0.036). CONCLUSIONS: A 2-point increase in modified HAI score after antiviral therapy is associated with increased progression to liver complications. © 2008 Lippincott Williams & Wilkins, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/172966
ISSN
2015 Impact Factor: 3.163
2015 SCImago Journal Rankings: 1.274
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_US
dc.contributor.authorLeung, Nen_US
dc.contributor.authorShek, WHen_US
dc.contributor.authorZhang, HYen_US
dc.contributor.authorLuk, JMen_US
dc.contributor.authorPoon, RTPen_US
dc.contributor.authorLo, CMen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorLau, GKKen_US
dc.date.accessioned2012-10-30T06:26:07Z-
dc.date.available2012-10-30T06:26:07Z-
dc.date.issued2008en_US
dc.identifier.citationJournal Of Clinical Gastroenterology, 2008, v. 42 n. 5, p. 533-538en_US
dc.identifier.issn0192-0790en_US
dc.identifier.urihttp://hdl.handle.net/10722/172966-
dc.description.abstractBACKGROUND: The modified histology activity index (HAI) score has been extensively used as an additional primary or secondary end point in most phase III pivotal therapeutic clinical trials on chronic hepatitis B. Improvement in modified HAI after antiviral therapy has usually been defined as a 2-point reduction in modified HAI score. AIM: We studied whether a 2-point change in modified HAI score after antiviral therapy for chronic hepatitis B is associated with progression to liver complications (decompensated cirrhosis or hepatocellular carcinoma). METHOD: Eighty-nine patients treated with interferon-α with liver biopsy before and at 6 to 12 months after the end of therapy were followed-up for a median 119.4 months. RESULTS: At the time of analysis, 11 patients (12.4%) had liver complications. Liver complications were higher in patients with a 2-point increase in modified HAI score [8 of 19 patients (42.1%) vs. 3 of 70 patients (4.3%), P=0.0002] and in those with severe fibrosis at end of therapy [6 of 19 patients (31.6%) vs. 5 of 70 patients (7.1%), P=0.010]. On Cox regression analysis, a 2-point increase in modified HAI score was associated with increased liver complications (relative risk 5.564, P=0.036). CONCLUSIONS: A 2-point increase in modified HAI score after antiviral therapy is associated with increased progression to liver complications. © 2008 Lippincott Williams & Wilkins, Inc.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.comen_US
dc.relation.ispartofJournal of Clinical Gastroenterologyen_US
dc.rightsJournal of Clinical Gastroenterology. Copyright © Lippincott Williams & Wilkins.-
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntiviral Agents - Therapeutic Useen_US
dc.subject.meshCarcinoma, Hepatocellular - Epidemiology - Etiology - Pathologyen_US
dc.subject.meshDna, Viral - Analysisen_US
dc.subject.meshDisease Progressionen_US
dc.subject.meshEnzyme-Linked Immunosorbent Assayen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHepatitis B Antibodies - Analysisen_US
dc.subject.meshHepatitis B Surface Antigens - Analysisen_US
dc.subject.meshHepatitis B E Antigens - Analysisen_US
dc.subject.meshHepatitis B Virus - Genetics - Immunologyen_US
dc.subject.meshHepatitis B, Chronic - Drug Therapy - Pathology - Virologyen_US
dc.subject.meshHong Kong - Epidemiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshIncidenceen_US
dc.subject.meshLiver - Pathologyen_US
dc.subject.meshLiver Cirrhosis - Epidemiology - Etiology - Pathologyen_US
dc.subject.meshLiver Neoplasms - Epidemiology - Etiology - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrognosisen_US
dc.subject.meshProportional Hazards Modelsen_US
dc.subject.meshSeverity Of Illness Indexen_US
dc.subject.meshTime Factorsen_US
dc.titleChanges in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complicationsen_US
dc.typeArticleen_US
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.authorityLuk, JM=rp00349en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/MCG.0b013e31804bbdffen_US
dc.identifier.pmid18344885-
dc.identifier.scopuseid_2-s2.0-42449104445en_US
dc.identifier.hkuros141601-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-42449104445&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume42en_US
dc.identifier.issue5en_US
dc.identifier.spage533en_US
dc.identifier.epage538en_US
dc.identifier.isiWOS:000255419400019-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridHui, CK=35082057900en_US
dc.identifier.scopusauthoridLeung, N=26643107200en_US
dc.identifier.scopusauthoridShek, WH=6701476327en_US
dc.identifier.scopusauthoridZhang, HY=8965962000en_US
dc.identifier.scopusauthoridLuk, JM=7006777791en_US
dc.identifier.scopusauthoridPoon, RTP=7103097223en_US
dc.identifier.scopusauthoridLo, CM=7401771672en_US
dc.identifier.scopusauthoridFan, ST=7402678224en_US
dc.identifier.scopusauthoridLau, GKK=7102301257en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats